Hemay181 is a potential first-in-class Topoisomerase I-targeted Sugar-based Drug Conjugate (SDC) drug, classified as a Class 1 innovative drug, designed for the treatment of solid tumors. The project is currently undergoing clinical trials in China and has also obtained clinical trial approval in the United States.
Hemay181 is currently conducting clinical trials for this indication in China. For detailed information on related clinical trials, please visitCLINICALTRIALS.GOV
